NDAORALTABLET, EXTENDED RELEASE
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
ZITUVIMET XR (sitagliptin and metformin hydrochloride) by Aurobindo Pharma is dipeptidyl peptidase 4 inhibitors [moa]. First approved in 2024.
Drug data last refreshed 6h ago · AI intelligence enriched 9h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZITUVIMET XR is a fixed-dose combination tablet containing sitagliptin (a DPP-4 inhibitor) and metformin hydrochloride in extended-release formulation, approved for oral use in type 2 diabetes management. The combination works by increasing incretin hormone activity to improve glycemic control while leveraging metformin's established insulin-sensitizing effects. This dual-mechanism approach targets patients requiring both agents for adequate blood glucose management.
Growth
Recent FDA approval in growth phase positions this product for rapid commercial team expansion; teams will focus on market penetration in competitive DPP-4 inhibitor segment.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
Started Jun 2024
34 enrolled
Healthy Subjects
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
Started Apr 2024
34 enrolled
Healthy Subjects
Career Relevance
Joining the ZITUVIMET XR team offers opportunity to launch a newly approved product in a high-volume therapeutic area with immediate commercial focus. Roles emphasize payer negotiation, formulary positioning, and field execution in a competitive small-molecule diabetes market with moderate growth potential.
Brand Manager
Worked on ZITUVIMET XR at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.